Skip to main content

Table 2 Cognitive function, body composition and IGF-I SDS of PWS adolescents at different stages in the study

From: Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial

 

Treatment schedule

p-value

Placebo/GH (n = 12)

GH/Placebo (n = 13)

After 1 year placebo

After 1 year GH

After 1 year GH

After 1 year placebo

Total IQ

61

(55 to 69)

62

(58 to 69)

69

(60 to 73)

70

(57 to 80)

0.832

Verbal IQ

62

(55 to 66)

65

(57 to 70)

66

(57 to 75)

67

(55 to 76)

0.486

 - Vocabulary

−2.3

(−2.7 to −2.0)

−2.2

(−2.9 to −2.0)

−2.3

(−3.0 to −1.3)

−2.0

(−2.7 to −1.5)

0.650

 - Similarities

−1.8

(−2.2 to −1.7)

−1.7

(−2.3 to −1.1)

−1.3

(−2.3 to −1.0)

−1.3

(−2.3 to −1.0)

0.943

 - Arithmetic

−2.0

(−2.2 to −2.0)

−2.0

(−2.0 to −1.7)

−2.0

(−2.0 to −1.7)

−2.0

(−2.0 to −1.8)

0.320

 - Digit Span

−2.2

(−2.8 to −1.7)

−2.3

(−2.9 to −1.8)

−2.0

(−2.3 to −1.8)

−2.0

(−2.3 to −1.8)

0.793

 - Information

−1.7

(−2.6 to −1.7)

−1.8

(−2.0 to −1.4)

−1.7

(−2.0 to −1.1)

−1.8

(−2.3 to −1.3)

0.154

 - Comprehension

−2.3

(−2.7 to −2.3)

−2.2a

(−2.6 to −2.0)

−2.0

(−2.6 to −1.4)

−2.0

(−2.6 to −1.4)

0.123

Performance IQ

59

(53 to 72)

57

(52 to 70)

67

(57 to 75)

69

(55 to 78)

0.322

 - Picture Completion

−2.2

(−2.9 to −1.7)

−2.5

(−2.9 to −1.7)

−1.7

(−2.8 to −0.8)

−1.3

(−2.3 to −0.4)

0.130

 - Coding

−3.0

(−3.0 to −2.2)

−2.7

(−3.0 to −2.3)

−2.5

(−3.0 to −1.5)

−2.3

(−3.0 to −1.5)

0.903

 - Block design

−2.0

(−2.2 to −1.4)

−1.5a

(−2.0 to −1.3)

−1.7

(−1.8 to −1.2)

−1.7

(−2.0 to −1.0)

0.075

 - Matrix Reasoning

−1.7

(−2.1 to −1.3)

−2.3a

(−2.3 to −1.7)

−2.2

(−2.3 to −1.2)

−2.2

(−2.3 to −1.3)

0.376

 - Picture Arrangement

−2.3

(−2.6 to −1.2)

−2.0

(−2.3 to −1.4)

−1.7

(−1.7 to −1.0)

−1.3

(−2.0 to −1.0)

0.611

FM%

45.3

(38.2 to 48.3)

41.7

(30.6 to 50.6)

39.3a

(33.2 to 49.8)

44.1

(38.4 to 52.3)

0.002

Lean body mass (kg)

32.3

(30.6 to 45.1)

34.6a

(31.6 to 44.0)

35.1

(32.6 to 41.3)

36.7

(31.5 to 39.2)

0.008

IGF-I SDS

−0.4

(−0.9 to −0.3)

2.1a

(0.0 to 2.4)

1.8a

(1.5 to 2.4)

−0.7

(−1.7 to 0.3)

<0.001

  1. Data expressed in SDS; median with IQR. P-value of mean difference between placebo and GH administration, tested by Wilcoxon tests
  2. awithin Placebo/GH or GH/placebo group; significantly different compared to placebo